Cardiomiopatia de Takotsubo da patogênese ao diagnóstico: estado da arte by Brito, Josué da Silva et al.
Rev Med (São Paulo). 2020 Sept-Oct;99(5):491-502.
491
doi: http://dx.doi.org/10.11606/issn.1679-9836.v99i5p491-502
Takotsubo cardiomyopathy from pathogenesis to diagnosis: state-of-the-art 
Cardiomiopatia de Takotsubo da patogênese ao diagnóstico: estado da arte
Josué da Silva Brito1, Marcela Silveira Castro1, Pâmela da Silva Zambianco1, Michelly Rodrigues 
Cavalcante1, Victória Araújo Silva1, Nicolli Bellotti de Souza2, Lucélia Rita Gaudino Caputo3
Brito JS, Castro MS, Zambianco PS, Cavalcante MR, Silva VA, Souza NB, Caputo LRG. Takotsubo cardiomyopathy from pathogenesis 
to diagnosis: state-of-the-art / Cardiomiopatia de Takotsubo da patogênese ao diagnóstico: estado da arte. Rev Med (São Paulo). 2020 
Sept-Oct;99(5):491-502.
Scientific presentation: Scientific presentation in I Cardiology and Pediatric Surgery Congress of University Center Atenas (UniAtenas) performed 
on May 22 to 23, 2018.  
1. Internos de Medicina do Centro Universitário Atenas (UniAtenas), Paracatu, MG, Brasil. ORCID: Brito JS: https://orcid.org/0000-0003-
2142-3689, Castro MS: https://orcid.org/0000-0003-2160-5925; Zambianco PS: https://orcid.org/0000-0003-0509-3878, Cavalcante MR: 
https://orcid.org/0000-0003-2490-1914; Silva VA: https://orcid.org/0000-0003-4463-7620. E-mails: josuedasilvabrito1998@gmail.com, 
marcelas.castro@hotmail.com, pamelazambianco@hotmail.com, Michellyr.c@hotmail.com, victoria.ramalho@hotmail.com.
2. PhD em Ciências. Orientadora Científica do Setor de Iniciação Científica e Pesquisa, Centro Universitário Atenas (UniAtenas), Paracatu, 
MG, Brasil. ORCID: https://orcid.org/0000-0001-8440-1482. E-mail: nicolli.atenas@hotmail.com.
3. Médica Patologista, Mestre em Ciências Morfofuncionais. Departamento de Clínica Médica, Faculdade Atenas, Passos, MG, Brasil. ORCID: 
https://orcid.org/0000-0002-7350-8521. E-mail: luccaputo@gmail.com.
Correspondence: Josué da Silva Brito. Rua das Mansões, 210, B. Esplanada, Paracatu, MG, Brasil. CEP: 38.608-230. E-mail: 
josuedasilvabrito1998@gmail.com 
ABSTRACT: Takotsubo cardiomyopathy (TCM) is a condition 
typically characterized by hypokinesia, dyskinesia or transient 
akinesia of the left ventricle apex. It lasts up to four weeks 
and is triggered by physical or emotional stress. With higher 
incidence among postmenopausal women, it consists of a clinical 
syndrome mistaken for acute myocardial infarction (AMI), due 
to the common clinical and laboratory findings. Approximately 
2 of every 100 acute coronary syndrome diagnoses are in fact 
TCM. Although it was described in 1990 and requires different 
therapy, international consensus on diagnostic criteria is still 
lacking. This article seeks to review the publications of the last 
30 years on the topic concerning epidemiology, pathogenesis, 
clinical manifestations, laboratory findings, diagnostic methods 
and criteria, in order to list measures that enable differentiating 
AMI from TCM in clinical practice.
Keywords: Takotsubo cardiomyopathy; Ventricular dysfunction; 
Ventricular dysfunction, left; Acute myocardial infarction.
RESUMO: A cardiomiopatia de Takotsubo (CMT) apresenta-se, 
normalmente, por hipocinesia, discinesia ou acinesia transitória 
do ápice do ventrículo esquerdo, com duração de até quatro 
semanas, desencadeada por estresse físico ou emocional. Com 
maior incidência entre mulheres pós-menopausa, consiste em 
uma síndrome clínica confundida com infarto agudo do miocárdio 
(IAM), devido aos achados clínicos e laboratoriais em comum.  A 
cada 100 diagnósticos feitos de síndrome coronariana aguda, cerca 
de 2 tratam-se da CMT. Apesar de ter sido descrita em 1990 e 
exigir terapêutica distinta, ainda não há consenso internacional no 
que se refere aos critérios diagnósticos. Este artigo busca revisar 
as publicações dos últimos 30 anos sobre o tema em relação 
a epidemiologia, patogênese, manifestações clínicas, achados 
laboratoriais, critérios e métodos diagnósticos, enumerando 
medidas que permitam diferenciar IAM de CMT na prática clínica.
Descritores: Cardiomiopatia de Takotsubo; Disfunção ventricular; 
Disfunção ventricular esquerda; Infarto agudo do miocárdio.  
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INTRODUCTION 
Takotsubo cardiomyopathy (TCM) or Takotsubo syndrome, also known as stress-induced 
cardiomyopathy, apical ballooning syndrome or broken 
heart syndrome, is a reversible and acute form of heart 
failure. It is characterized by reduced fraction of ejection 
and associated with emotional or physical stress, that 
usually lasts up to four weeks1-6. It was initially described 
by Sato et al.1 in 1990, having the anterolateral elevation of 
the ST segment and transient antero-apical dyskinesia with 
compensatory basal hyperkinesia as main characteristics. 
TCM mimics chest pain and other symptoms and 
signs of acute coronary syndrome (ACS), especially 
acute myocardial infarction (AMI), as well as common 
electrocardiographic aspects, which is why about 1.7% to 
2.2 % of the initial diagnoses of ACS are actually TCM. 
For this reason, it is a disease of great importance and 
should always be considered as a differential diagnosis of 
acute chest pain4,7-9.
The nomenclature of this cardiomyopathy refers 
to the similarity observed by the descriptors of the 
disease between the Japanese trap (Tsubo) used to capture 
octopuses (Tako) and the aspect exhibited by the ventricle 
affected at the end of the systole, in the ventriculogram4,9,10.
Th is  a r t i c le  seeks  to  address  ep idemiology, 
pathophysiological aspects, clinical manifestations and 
laboratory findings on TCM from original studies, reviews 
and reports published in the last 30 years, gathering data 
that facilitate the differentiation between ACS and TCM 
by the clinical physician.
METHODS 
 Research was carried out in PubMed / Medline, 
Scopus, Google Scholar, SciELO, Lilacs and institutional 
thesis and dissertation libraries using the terms “takotsubo 
cardiomyopathy”, “takotsubo syndrome”, “apical 
ballooning”, “cardiomyopathy by stress”. Original articles, 
review studies and case reports, in English, Spanish and 
Portuguese, published from 1990 and 2020, were included, 
resulting in 115 articles. 
EPIDEMIOLOGY 
 There is no consensus regarding the annual 
incidence of TCM, either due to the difficulty of carrying out 
surveys, or due to the lack of recognition of the syndrome 
by health services. The syndrome has an estimated annual 
incidence between 0.00006% to 0.05%. About 90% of the 
cases occur in postmenopausal women, aged between 62 
and 76 years; incidence in whites, African-Americans and 
Hispanics is 67.4%, 4.4% and 4.3%, respectively5,11-21.
In the United States, TCM incidence increased: 
from 2007 to 2012, the incidence increased from 52 cases 
/ 1,000,000 to 178 cases / 1,000,000 inhabitants (P <0.001), 
although in-hospital mortality of 1.1% remained unchanged 
during the period22.
The International Takotsubo Registry (InterTAK 
Registry) investigated 1,750 patients and showed that 
89.8% of cases were women, 66.8 ± 13.0 years-aged, of 
whom 79.1% were women over 50 years old23.
In 2008, Deshmukh et al.15 analyzed the National 
Inpatient Sample (NIS), the largest hospital database in the 
United States, and found 6,837 records of TCM patients 
which corresponded to an estimated prevalence 0.6 / 
100,000 inhabitants for men and 5.0 / 100,000 inhabitants 
for women. The female gender exhibited odds ratio (OR) 
equals to 8.8 (95% CI: 7.3-10.5) for the disease.  Women 
over 55 years old were 4.8 (95% CI: 4.2-5.6) times more 
likely to develop TCM than those under that age. Risk 
factors for other cardiovascular pathologies, such as 
dyslipidemia, stress, anxiety, smoking and alcoholism, 
were also significant risk factors for TCM15.
Despite being primarily associated with emotional 
or physical stressors, these are not always clear to medical 
research. Only 44% to 75% of investigations obtain data 
on some stressor factor prior to dyskinesia5,11,14.
Table 1 summarizes the physical and emotional 
stressors related to TCM.
Nevertheless, conventional cardiovascular risk 
factors should not be ruled out in the case of TCM patients. 
All patients included in the study performed by Cesario 
et al.10 showed at least one cardiovascular risk factor. 
Hypertension, the most common risk factor, was present 
in 70% of patients. Dyslipidemia, the second most reported 
factor, was found in 60% of cases. There were also reports 
of obesity, type 2 diabetes mellitus and smoking as risk 
factors. 
The presence of mental disorders - depression, mood 
and anxiety disorders -, status epilepticus, family history of 
cardiovascular diseases and reduction of estrogen are also 
considered risk factors41,42.
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Table 1 - Stress factors related to Takotsubo cardiomyopathy6,10,11,24-43
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Dissonant to the advancement of knowledge about 
several cardiovascular diseases, the exact pathogenesis of 
TCM remains unknown. However, the interaction of several 
mechanisms, such as coronary spasms, microvascular 
dysfunction, transient coronary occlusion, estrogen 
deficiency and sympathetic changes, is suggested5,44-46. 
Coronary spasms and microvascular dysfunction 
Transient coronary spasms and reduced blood flow 
are frequent in TCM. Provided that spasms are estimated 
to occur in 21% to 54% of patients, it was one of the first 
hypotheses raised for pathophysiology1-3,44-50.
This hypothesis has been the subject of several 
investigations. Patel et al.50 reported vasoconstriction of the 
epicardial coronary artery in 60% of patients submitted to a 
vasomotricity test, as well as microvascular dysfunction – 
most frequently in the epicardial arteries – in 90% of them. 
Another study with 47 patients, 46 female and 1 male, aged 
67 ± 12 years, reported abnormal coronary vasoconstriction 
in 85% of patients. Microvascular dysfunction was present 
in 83% of patients51. Loffi et al.52 evaluated 27 TCM 
patients, 27 patients with microvascular angina and 27 
patients in a control group (CG), measuring the flow of 
the anterior descending artery (AD), right coronary artery 
(RCA) and left circumflex artery (LCX) arteries using the 
frame count of the Thrombolysis in Myocardial Infarction 
(TIMI) frame count (TFC). TCM in AD showed a TFC of 
22 ± 8 vs GC 15 ± 4 (p = 0.001). Regarding RCA, TCM 
group had TFC equals to 12 ± 4 vs GC 10 ± 3 (p = 0.025); 
in the case of LCX, TFC for TCM group was 14 ± 4, while 
it was 11 ± 3 for CG (p = 0.006).
Despite these studies, it is not possible to define 
whether the vasomotricity abnormalities occur prior 
to cardiomyopathy or represent results of the clinical 
condition, thus hindering the elucidation of TCM 
pathogenesis53. 
There are also studies that do not point to any 
microvascular dysfunction. In an analysis of 17 patients 
aged 54 to 91 years, Abe et al.54 did not report significant 
findings on abnormalities in the coronary microcirculation 
or reduced flow. Another study that evaluated 59 female 
patients, aged 32 to 90 years, showed no significant change 
in the epicardial coronary arteries flow or alteration in the 
microcirculation55. 
In addition to coronary spasms, spontaneous 
coronary artery dissection is considered as the probable 
genesis of an ischemic process that results in cardiac 
stunning and TCM6,44,56,57.
Transient coronary occlusion and atheromatous plaque
Although initially proposed as a mechanism 
associated with cardiac dysfunction, retrospective studies 
ruled out atheromatous plaque rupture as a possible 
contributor to TCM pathogenesis, since the changes are 
not limited to the specific territory of any coronary artery. 
Obstructions are generally lower than 50% unlike what 
occurs in acute myocardial infarction48. Plaque changes 
present in TCM are also found in stable angina and even 
in asymptomatic patients58.
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Estrogen deficiency
Several vascular effects are linked to estrogen: the 
ability to modulate vascular tone, supra-regulation of the 
endothelial enzyme nitric oxide synthase and inhibition of 
endothelial apoptosis59.  Estrogen deficiency is therefore 
associated with a greater propensity for microvascular 
spasms, along with endothelial dysfunction and increased 
sympathetic stimuli, which explains the higher incidence 
of TCM in postmenopausal women5,12,44,46. In fact, a study 
showed that ovariectomized female Sprague-Dawley® 
rat exhibited more severe cardiac dysfunction and higher 
troponin concentrations60.
The possible influence of estrogen led to the 
investigation of estrogen receptor polymorphism (ESR) 1 
and 2. Studies involving healthy, AMI and TCM patients 
showed a risk relationship between allele T in the ESR1 
rs2234693 locus and in the ESR2 rs1271572 locus with 
TCM61,62.
Considering that estrogen supplementation as 
a prophylaxis for TCM is still controversial, there is 
no consensus on recommendations. In animal studies, 
association of estrogen supplementation with alpha and 
beta-blockers reduced sympathetic stimuli induced by 
stress and increased cardioprotective substances5,12,44-46.
Sympathetic activation and increased catecholamines 
 Physical and psychological stress triggers a brain 
activating response, increasing the release of cortisol 
and catecholamines. Different stimuli processed by the 
hypothalamus, cingulate gyrus and amygdala stimulate 
the production and secretion of norepinephrine by the 
locus coeruleus and the production of epinephrine40,41,56. 
Elevations of 7 to 34 times of epinephrine have already 
been found in patients with TCM, although there is no 
consensus as to the mechanisms that link the elevation of 
epinephrine to cardiac dysfunction40,41,48,56.
Discharge of catecholamines, released upon stress 
episodes, is suggested to act directly on the myocardium 
through sympathetic innervation. It generates calcium 
overload in the cardiomyocytes, thus producing the 
typical lesion of contraction band necrosis, characterized 
by hypercontrolled sarcomeres, intensely eosinophilic 
transversal bands, with interstitial mononuclear 
inflammatory response19,40,57,63-67. Catecholamines also 
stimulate the release of vascular endothelial growth 
factors (VEGF), epidermal growth factor (EFG) and 
interleukins, but the role of inflammatory reaction in the 
acute presentation of TCM has not yet been elucidated66.
The hypothesis of catecholamines involvement 
in the pathogenesis of TCM is in line with the regional 
differences observed for beta 2 adrenergic receptors, as 
they are present in higher intensity in the left ventricular 
apex region. In these patients, catecholamines response, 
which has ionotropic and chronotropic action, is such 
that it causes a switch from the stimulatory G protein 
(Gs) to inhibitory (Gi). This event is supposed to protect 
the myocardium from further damage, but in this case, it 
apparently generates a negative inotropic response66.
 Pelliccia et al.40 propose a synthesis of the evidence. 
They suggest the possibility of a pathophysiological process 
characterized by a high concentration of catecholamines 
and coronary spasm during the acute phase of the syndrome, 
which increases energy expenditure as well as reduces 
blood supply r. In other words, an imbalance between 
supply and demand is stablished, generating a myocardial 
stun and changes in glucose and fatty acids metabolism. 
None of the mechanisms suggested so far, however, 
satisfactorily explained the pathophysiology of TCM68.
MANIFESTATIONS 
 As in ACS, the most frequent manifestation of 
TCM is chest pain, which occurs in 75 to 80% of cases. 
This pain is mild to moderate at rest, which may be 
accompanied by dyspnea (20–46.9%), syncope (7.7%), 
palpitations, hypotension, nausea, vomiting, arrhythmias, 
febrile syndrome and important bradycardia. Unusual initial 
manifestations (20%) include heart failure and cardiogenic 
shock11,16,22,34,66,69-73. 
The initial presentation is easily confused with 
ACS and it is not always possible to establish the initial 
stressful event, making the differentiation even more 
complex57. It is worth noting, however, that AMI and TCM 
coexist in some patients. AMI has been suggested as a 
triggering factor, since the condition may cause elevation 
of catecholamines74-77. 
Whether TCM is a cardiomyopathy or not is still 
controversial. There is a suggestion that it may be an 
ACS. It presents myocardial ischemia, troponin elevation, 
ventricular abnormalities and electrocardiographic changes 
features of ACS. Besides, clinical presentation and possible 
pathophysiology differ from other cardiomyopathies78.
ELECTROCARDIOGRAM CHANCES 
 The electrocardiographic findings vary depending 
on the time of progression of cardiomyopathy. Most 
commonly, there is an elevation of the ST segment (mainly 
in the precordial leads), negative T wave, Q waves or 
abnormal progression of the R waves - changes also 
common to AMI - as well as prolongation of the corrected 
QT interval (QTc)54,55,79,80. Initially, ST elevation is observed 
(lower than that observed in AMI). Subsequently, the 
condition progresses with inversion of the T wave, with 
the first peak of negativity within three days after the onset 
of symptoms. Between the second and the sixth day, there 
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is a transient resolution of the negative T wave and the 
ST elevation ends. Afterwards, deeper negative T waves 
appear, with longer QTc interval prolongation, which may 
persist for two to four months5 ,6,11,12,81,82.
Some electrocardiographic criteria have been 
proposed to differentiate between AMI and TCM (Table 
2). The highest sensitivity criterion is represented by the 
absence of reciprocal changes in lower leads, while a 
concomitant elevation of ST in aVR, anteroseptal and lower 
leads represents the highest specificity criterion.
Table 2 - Synthesis of the main electrocardiographic findings in differentiating TCM from other syndromes83-88
Electrocardiographic criteria Sensitivity Specificity
Absence of reciprocal changes in inferior leads 100% 69%
STE in aVR in the absence of STE in V1 96% 96%
Positive T wave in aVR in the absence of negative T wave in V1 95% 94%
Absence of abnormal Q 83% 69%
STE in V4–6/ STE in V1–3 ≥ 1 80% 77%
STE in V3-5 ≥ 1mm in the absence of STE in V1 ≥ 1mm 74,2% 80,6%
STE V in 3 ≥ 1mm in the absence of STE in V1 ≥ 1mm 67,7% 80,7%
STE in lead II ≥ 1mm 62,5% 92,6%
STE in aVR together with ST Supra in the lower and anteroseptal leads 12% 100%
Subtitle: STE: ST-segment elevation 
TCM MARKERS
There is no consensus on the exclusive markers of 
TCM or their diagnostic values. There are markers common 
to TCM and AMI88.
Despite its role in pathophysiology, the increase 
in catecholamines, unlike expectations, is not always 
present87. Mandhavan et al.89 assessed the levels of 
normetanephrine and metanephrine in 10 patients with AMI 
and 19 with TCM and did not find significant differences 
(respectively, 0.64 nmol / l —  95% CI: 0.43-0.97 — vs 0.53 
nmol / l — 95% CI: 0.32-0.70 —, p = 0.44, and 0.10 nmol 
/ l — 95% CI: 0.10-0.22 — vs 0.16 — 95% CI: 0.10-0.38 
—, p = 0.29) between the two groups, in addition to having 
found normal urinary metanephrine levels in the 24-hour 
urine test in TCM group. Christensen et al.90 evaluated 
32 TCM patients and found no significant differences in 
plasma norepinephrine. 
On the other hand, Wittstein et al91 found plasma 
norepinephrine levels of 2284 pg/mL (1709–2910) vs 1110 
pg/mL (914–1320) (p <0.005) upon the evaluation of 19 
patients, 13 with TCM and 7 with IAM Killip III. The 
catecholamine values were 2 to 3 times higher in TCM 
group compared to AMI group.
Taken together, studies suggest caution in 
determining catecholamines as diagnostic markers 90 and 
there is little practical application.
Related to stress, cortisol is also evaluated as a 
biomarker for TCM87. Mandhavan et al.89 showed nocturnal 
plasma elevation in up to 50% of patients in the initial 
phase, whereas 23% of the control group also had elevated 
levels and all TCM patients had normal urinary levels.
In TCM, markers of myocardial injury, such as 
troponin, lactic dehydrogenase (DHL), myoglobin, creatine 
phosphokinase MB (CK-MB), are present, but at a lower 
degree of variation in comparison to AMI cases. Troponin, 
for example, is present at levels up to 7 times lower than 
those observed in AMI; its levels rise in approximately 
90% of patients87,89. Most patients, therefore, may show a 
modest troponin elevation92.
Agewall et al.92 quantified troponin levels in patients 
with ACS and TCM and suggested cutoff points for both 
diseases. Table 3 sintetizes the findings. 
In a review of 114 cases, minimum, maximum 
and average values of troponin I and T, CK and CK-MB 
(Table 3) were measured using different kits. The authors 
concluded that troponin T levels higher than 6 ng / mL 
or troponin I above 15 ng / mL are unlikely in TCM and, 
therefore, these can be considered cutoff points. A moderate 
correlation between troponin T level and initial ejection 
fraction (R2 = 0.6) was also shown93. 
Table 3 - Expected values of biomarkers present at TCM 67
Biomarker Minimum value Maximum value Mean
Troponine I (ng/mL) 3 13 6.5
Troponine T (ng/mL) 3 7 3.6
CK (U/L) 20 3,395 556.1
CK-MB (U/L) 2 111 32.,9
Subtitle: CK: creatine phosphokinase; CK-MB creatine phosphokinase MB 
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Already considered as markers for AMI, the 
N-terminal fragment of the cerebral B natriuretic 
pro-peptide type (NT-proBNP) and the B-natriuretic 
peptide (BNP) are considered as promising markers of 
TCM. They are released at the time of baseline cardiac 
hypercontractility, with an increase proportional to 
sympathetic activation and level of cardiac dysfunction. 
The elevation occurs in the first 12 hours of symptoms, 
peaking in 24 hours, with mean BNP values of 617 pg / 
mL and NT-proBNP of 4,382 pg / mL82,89,94.
MicroRNAs (miR) have been investigated as 
potential markers for cardiovascular disease, since the 
expression is specific for each tissue and may reflect 
pathological states95. TCM patients have significant 
overloading of miR-16, miR-26a, miR-1 and miR-133a 
compared to healthy patients who have already had AMI. 
When the 4 miR are sought, the resulting marker has a 
sensitivity of 96.77% and specificity of 70.37% regarding 
the differentiation between TCM and AMI96.
Relationships for differentiation between AMI and TCM
Due to the difficulty of interpreting enzyme levels, 
relationships are proposed to help differentiate between 
TCM and AMI97. These relationships, together with 
sensitivity and specificity, are present in Table 4.
Table 4 - Relationships of proposed biomarkers for differentiation between AMI and TCM97-100
Relationship Sensitivity Specificity
BNP/TnT  ≥ 1,272 52% 95%
BNP/CKMB ≥ 29.9 50% 95%
NTproBNP /TnT ≥ 2,889 91% 95%
NTproBNP /TnT≥ 5,000 83% 95%
High sensitivity TnT /CKMB ≥ 0.015 85.7% 67.6%
High sensitivity TnT /CKMB ≥ 0.017 83.3% 78.1%
Units: BNP (pg/l); NTproBNP (ng/l); TnT (μg/l); myoglobin (μg/l). Acronyms: cerebral natriuretic peptide (BNT), creatine phosphokinase 
MB (CK-MB), N-terminal fragment of the pro-brain natriuretic peptide type B (NT-proBNP), Troponin T (TnT).
RADIOLOGICAL EXAMS
The essential and most frequently used test for the 
diagnosis of TCM is the echocardiogram. With the evolution 
of medical technologies, however, ventriculography and 
magnetic resonance have gained an essential role in TCM 
diagnosis87.
The echocardiogram is a practical, non-invasive 
technique, easy to use in the emergency care. It reveals, 
in the acute phase, apical ballooning caused by akinesia, 
dyskinesia or ventricular hyperkinesia. Typically, 
abnormalities are observed to extend beyond the 
distribution limits of a single artery. The classic and 
most frequent pattern consists of compensatory baseline 
hyperkinesia and apical dyskinesia, and is therefore 
called the apical type. Some variants, however, are 
described: mid-ventricular type, which is characterized 
by hypokinesia in the middle region of the ventricle, with 
preservation of the apex; basal type, also called inverted 
TCM, which consists of basic hypokinesia with apex and 
middle region preservation (related to pheochromocytoma 
and subarachnoid hemorrhage); isolated focal type, 
characterized by dysfunction of cardiac segments; global 
type (or biventricular TCM), composed of hypokinesia in 
all cardiac segments, besides being associated with a higher 
risk of complications and hemodynamic instability; and 
reverse mid-ventricular type, described as hyperkinesis 
of the mid-ventricular region with akinesia or apex and 
base hypokinesia, isolated right ventricular involvement 
and ventricular apical dysfunction9,11,56,87,100-106.
The typical presentation usually corresponds to 70-
85% of the cases, while the ventricular apex is spared in 
15% of the cases66. Regarding presentation morphologies, 
Kato et al.107 reported 144 cases, 59% of which were basal 
type, 49% mid-ventricular type and 6.9% focal type, all 
having basal-septal segment abnormality, whereas Templin 
et al.108 reported the following frequencies: 81.7% for the 
apical pattern, 14.6% for the mid-ventricular pattern, 2.2% 
for the basal pattern and 1.5% for the focal pattern.
The echocardiogram may also contribute to the 
detection of left ventricular outflow obstruction, which is 
found in 10% to 25% of TCM patients. Conventional and 
contrast 2D have, respectively, 56% to 72% and 88% to 
96% sensitivity and thus are used for diagnosis108-111. 
Coronary angiography and ventriculography are 
invasive methods capable of detecting, respectively, 
coronary lesions, when they are present, and ventricular 
hypokinesia, dyskinesia and akinesia, allowing the 
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identification of ballooning and the same similar image 
patterns described for cardiac echocardiography100. In 
coronary angiography, patent arteries without obstruction 
and injuries are usually found98,101. In some patients, rupture 
of atheromatous plaque and transient thrombotic occlusion 
may be observed95. In 86.5% of the patients, left ventricular 
ejection fraction is reduced, verifiable by ventriculography, 
while the left ventricular end diastolic pressure is increased 
in 93% of patients105. Figure 1 depicts the findings during 
diastole and systole in ventriculography. 
Figure 1 – Ventriculography of Takotsubo cardiomyopathy in diastole (A) and systole (B), showing apical ballooning. Adapted from 
Góes et al.101
Angiotomography can also be useful in the 
investigation of TCM, as well as in case of suspected TCM 
in order to exclude coronary obstruction112.
Magnetic resonance imaging allows the assessment 
of anatomical patterns, movement variability of the 
ventricular wall and quantification of function and 
extracellular volume, in addition to providing information 
on pericardial and pleural effusions and on the presence 
of thrombi. This enables the differentiation of a reversible 
dysfunction, TCM, which is characterized by edema and 
inflammation, from an irreversible condition, such as AMI, 
characterized by necrosis and fibrosis87,95.
The scintigraphy imaging can also be employed 
using123IMIBG, a radioactive marker analogous to 
norepinephrine. The exam assesses the uptake, storage 
and release of the marker, providing information on 
sympathetic nerve activity95,100. In a patient with TCM, 
there is sympathetic hyperactivity, but with reduced marker 
uptake in regions of akinesia. Nevertheless, scintigraphy 
imaging has limited practical application96.
DIAGNOSTIC CRITERIA
Various diagnostic criteria have been proposed for 
assessment of TCM, given the difficulty in recognizing 
the pathology and differentiating it from an ACS. The first 
criteria were suggested in 2003 by Japanese researchers. 
Since then, several European, American, and Japanese 
organizations, as well as individual authors have proposed 
new observations on the diagnosis, but there is still no 
consensus on it112,113.
Although little appreciated, the criteria of the Mayo 
Clinic, initially proposed in 2004 and revised in 2008, 
are widely disseminated112-113. The criteria presuppose 
the mandatory presence of four conditions to establish 
the diagnosis of TCM: a) hypokinesia, akinesia or 
transient dyskinesia of the middle segment, including the 
apical segment or not, exceeding the epicardial vascular 
distribution; b) absence of obstructive coronary disease 
or evidence of acute plaque rupture at angiography; c) 
recent abnormality on the electrocardiogram (ST-segment 
elevation and / or T-wave inversion) or modest elevation 
of cardiac troponin; d) absence of pheochromocytoma and 
myocarditis114.
Given that the Mayo Clinic criteria have clinical 
limitations, a new form of diagnosis has been proposed: 
the InterTAK diagnostic score112,113. The InterTAK score 
has seven variables, each one representing a score value: 
female (score = 25); emotional trigger (score = 24); physical 
trigger (score = 13); absence of ST segment depression 
(score = 12), except in aVR; psychiatric disorders (score 
= 11); neurological disorders (score = 9); prolongation 
of the QTC (score = 6), totaling 100 points. A score ≥ 50 
represents a sensitivity of 94.7% for the diagnosis of TCM. 
The cutoff value of 40 points has a sensitivity of 89% 
and specificity of 91%115. This score takes into account 
the focal TCM and does not rule out the possibility of 
pheochromocytoma or AMI in the patient’s history, unlike 
the Mayo Clinic criteria112.
498
Rev Med (São Paulo). 2020 Sept-Oct;99(5):491-502.
CONCLUSION
Although reported 30 years ago, there is still no 
exact description of the pathophysiology of Takotsubo 
cardiomyopathy, even though the different findings 
suggest the interaction of the various mechanisms already 
proposed. Besides that, a universally accepted diagnostic 
criterion has not been established yet, which leads to several 
misdiagnoses. Further research using animal models is 
necessary to understand the pathogenesis complexity and 
thus clarify it. It is also necessary to disseminate knowledge 
about the diagnosis and the very existence of the disease, in 
order to avoid underdiagnosis and facilitate the recognition 
of pathology in emergency care.
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